Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib versus ofatumumab in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
2012-000694-23Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ibrutinib with Ofatumumab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
ibrutinibofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-000694-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000694-23.